On May 19, 2020, the board of directors of Adial Pharmaceuticals, Inc. appointed Dr. Jack Reich to serve as a Class III member of the Board. The appointment, which is effective immediately, means that the size of the Board will be seven members. Dr. Reich will serve on the audit committee and the nominations and corporate governance committee, and his term will expire at the Company’s 2021 Annual Meeting of Stockholders and until such time as his successor is duly elected and qualified, or until his earlier resignation or removal. Dr. Jack Reich’s career spans over 35 years in the pharmaceutical, biotechnology, and venture capital industries. He began his career at Bristol-Myers International. While working at Bristol-Myers, Dr. Reich pursued his Ph.D. His dissertation was the first in the area of international drug development and registration.